EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSBTAG00000006101
Gene Symbol: PSMD4
119 Enzyme and pathways 5 Cross references
299 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSBTAG00000005426
Gene Symbol: PSMC1
121 Enzyme and pathways 5 Cross references
328 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSBTAG00000046712
Gene Symbol: PSMC2
120 Enzyme and pathways 5 Cross references
240 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSBTAG00000021744
Gene Symbol: PSMC3
120 Enzyme and pathways 5 Cross references
240 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSBTAG00000009414
Gene Symbol: PSMC4
119 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSBTAG00000021061
Gene Symbol: PSMC5
119 Enzyme and pathways 5 Cross references
238 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSBTAG00000015732
Gene Symbol: PSMC6
119 Enzyme and pathways 5 Cross references
248 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSBTAG00000005119
Gene Symbol: PSMD1
120 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSBTAG00000018897
Gene Symbol: PSMD11
120 Enzyme and pathways 5 Cross references
295 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSBTAG00000002423
Gene Symbol: PSMD12
120 Enzyme and pathways 5 Cross references
234 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSBTAG00000002045
Gene Symbol: PSMD13
120 Enzyme and pathways 5 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSBTAG00000021691
Gene Symbol: PSMD14
121 Enzyme and pathways 5 Cross references
225 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).